

Please circulate to others and file in your *Provider Manual* for future reference.

January 9, 2018

## **2017-2018 Respiratory Syncytial Virus (RSV) Season**

Children's Primary Medical Group (CPMG) will continue to assume full responsibility for the authorization and administration of Palivizumab (Synagis) for all CHG members for the 2017-2018 RSV Season. Due to established regional patterns of RSV prevalence, some areas, including San Diego, will administer Synagis on a delayed schedule relative to most of the country. Synagis administration will begin on **Dec 1, 2017** and end on **April 30, 2018**.

### ***What does this mean?***

It means that all requests for Synagis for CHG members will be managed by CPMG. Synagis will be administered in a dedicated clinic via the Rady Children's Hospital Infusion Center. The **only** form that will be used is the **CPMG Authorization Request for Synagis** that is included with this Provider Alert. Please complete this new form and fax to CPMG Customer Services department at (858) 307-7977. Should you have any questions, please direct your inquiries to CPMG at (877) 276-4543.

### **Important to remember:**

- The American Academy of Pediatrics (AAP) has not changed its guidelines for the use of Synagis for the 2017-2018 season.
- Synagis is not recommended for otherwise healthy infants born at or after 29 weeks, 0 days' gestation
- A maximum of 5 doses will be given
- Synagis is no longer recommended for children in the 2<sup>nd</sup> year of life except for Children who require at least 28 days of oxygen after birth and who continue to require medical treatment (oxygen, steroids, or diuretic therapy).
- Monthly Synagis injections should be discontinued in any child who requires Hospitalization for breakthrough RSV.

If you have any questions, please feel free to contact me at (619) 240-8936.

**Charles Lino, PharmD**  
Pharmacy Director, Community Health Group